Form 4: Castle Biosciences CEO Sells Shares Under 10b5-1 Plan

Castle Biosciences President and CEO Derek J. Maetzold sold 1,339 shares of common stock for approximately $22.44 per share under a pre-arranged 10b5-1 plan.

Summary

• Derek J. Maetzold, President & Chief Executive Officer and Director of Castle Biosciences Inc. (CSTL), sold 1,339 shares of common stock.
• The transaction occurred on October 20, 2025, at a weighted-average price of $22.44 per share, with trades ranging from $22.290 to $22.615.
• The sale was executed pursuant to a Rule 10b5-1 plan adopted by Maetzold on May 8, 2025.
• Following this transaction, Maetzold directly owns 62,988 shares and indirectly owns 260,472 shares through various trusts.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to an insider sale, but significantly mitigated by the fact it was executed under a pre-arranged 10b5-1 plan, which suggests a planned liquidity event rather than a reaction to new negative information. The relatively small number of shares sold compared to total holdings also limits the negative impact.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned liquidity event for personal financial management rather than a reaction to new, negative company information.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the direct ownership stake of a key executive, which can sometimes be perceived with slight caution by investors.

Risks

• The sale by a key executive, even if pre-planned, could be misinterpreted by some market participants as a lack of confidence, potentially leading to short-term negative sentiment.

Future Outlook

NA

Industry Context

This transaction represents a routine insider stock sale under a pre-arranged plan, a common practice among executives for personal financial planning. It does not inherently reflect on broader industry trends or competitive positioning for Castle Biosciences.

Related Party Transactions

• Derek J. Maetzold indirectly holds shares through various trusts, including The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, several Maetzold 2018 Remainder Trusts, and DJM Grantor Retained Annuity Trusts. These trusts are considered related parties.

Stakeholder Impact

• Shareholders may perceive a slight negative signal from an insider sale, though the 10b5-1 plan mitigates this. The overall impact on share price is likely minimal given the small number of shares sold relative to the company's market capitalization.

Key Dates

Recommendation

The filing reports a routine insider sale by the CEO under a pre-arranged 10b5-1 plan. This type of transaction is typically for personal financial planning and does not usually signal a change in the company's fundamental outlook or performance. While any insider sale can be viewed with caution, the pre-planned nature and the relatively small number of shares sold (1,339 shares) compared to the CEO's total direct and indirect holdings (over 320,000 shares) suggest it is not a strong indicator for a 'sell' recommendation. Without additional information on company performance or market conditions, a 'hold' recommendation is appropriate as this filing alone does not provide a strong catalyst for a change in investment thesis.

Keywords

Castle Biosciences, CSTL, Derek Maetzold, Insider Sale, Form 4, 10b5-1 Plan, CEO, Director, Stock Transaction